top of page

Nishant Rastogi, MBA

Vice President

Nishant joined New Rhein in 2018 and leads the Fund’s Transactions team. He is a founding member of the Philadelphia office. Nishant is responsible for the identification and screening of new opportunities, due diligence, negotiation of deal structure, and portfolio company involvement. His deal experience includes Softhale (exited to Sino Biopharma), Neuraptive Therapeutics, American Injectables, Butterfly Medical, Saayva Pharmaceuticals, and Theranica Bioelectronics. 


Prior to New Rhein, Nishant was the first associate at Broadview Ventures, a mission-driven fund focused on accelerating the development of promising technologies for the treatment of cardiovascular disease. In addition to deal and portfolio responsibilities at Broadview, he helped publish an article in the Journal of the American College of Cardiology on the importance of impact investing in life sciences. He has since advised multiple scientific research foundations on the creation of mission-drive venture funds.

Nishant began his career in Corporate Strategy at Fidelity Investments. He holds an MBA from Northwestern University, a BA in Economics from Dartmouth College. 

bottom of page